sees fy sales $4.2 billion to $4.5 billion.
q4 adjusted earnings per share $1.01.
qtrly net sales rose 11 percent to $3.3 billion excluding our fine chemistry services business sold in june of 2021.
qtrly adjusted earnings per share $1.13.
q4 loss per share $4.
qtrly net sales increased 13 percent to $1.8 billion.
qtrly adjusted ebitda grew 13% to $871 million, surpassing upper end of guidance.
sees 2021 capital expenditures in range of $1.3 billion to $2.0 billion.